[Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer]

Rev Esp Quimioter. 2015 Oct;28(5):256-62.
[Article in Spanish]

Abstract

Introduction: Bloodstream infections due to multire-sistant Enterobacteriaceae are a major matter of concern nowadays. The present study evaluated the impact of these infections in our area.

Methods: Prospective observational study of a cohort of patients with bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases producing organisms among hospitalized patients in Cruces Hospital for 2 years. We conducted a descriptive analysis, a subgroup analysis (cancer vs. non-cancer patients) and a mortality analysis.

Results: During the study period, 3409 episodes of bacteraemia were diagnosed, of which 124 (3.6%) were ESBL and other beta-lactamases producing Enterobacteriaceae. 40.3% of the cases were nosocomial, 15.3% community acquired and 44.4% were health-care associated. 44.4% of the cohort had cancer as underlying disease. The most commonly isolated organism was E. coli (83% of cases), regardless of the source of infection. 58.1% of patients received inadequate empirical therapy. 7 day-mortality was 10.5% and 30 day-mortality was 21.8%. None of the analyzed variables showed association with 7 and 14 day-mortality, but the presence of solid cancer (p= 0.032) and advanced HIV infection (p = 0.027), were significantly associated with higher 30 day-mortality.

Conclusions: More than half of bacteraemia episodes affected outpatients and most of them were health-care associated episodes. Even though more than half of the patients received inadequate empirical treatment, this was not related to higher mortality. We only found an association between 30 day-mortality and the presence of underlying solid malignancy or advanced HIV infection.

Publication types

  • English Abstract
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / etiology
  • Bacteremia / microbiology*
  • Bacteremia / mortality
  • Bacterial Proteins / metabolism*
  • Cohort Studies
  • Cross Infection / microbiology*
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae Infections / etiology
  • Enterobacteriaceae Infections / microbiology*
  • Enterobacteriaceae Infections / mortality
  • Escherichia coli Infections / microbiology
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Neoplasms / complications*
  • Prospective Studies
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • AmpC beta-lactamases
  • beta-Lactamases
  • carbapenemase